{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"151","value":"663"},{"groupId":"OG001","spread":"51","value":"373"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"The AUC0-τ of relugolix was determined for single and repeat doses in subsets of participants from Japan. Single dose PK was assessed on Day 1 following an initial 360 mg dose of relugolix. Repeat dose PK was assessed following repeat dosing of relugolix 120 mg once daily for 2 weeks.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Relugolix oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix Single-Dose"},{"description":"Relugolix 120-mg tablet administered orally once daily for 2 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG001","title":"Relugolix Repeat-Dose"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"A subset of Japanese participants enrolled in study were included in the PK analysis.","reportingStatus":"POSTED","timeFrame":"Predose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose on Day 1 and Week 2","title":"Area Under The Concentration-Time Curve (AUC0-τ) Of Relugolix","type":"SECONDARY","unitOfMeasure":"ng⸳hr/mL"}